Giles Wilson Buys 202 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson purchased 202 shares of Dr. Martens stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average price of GBX 74 per share, for a total transaction of £149.48.

Giles Wilson also recently made the following trade(s):

• On Wednesday, May 13th, Giles Wilson acquired 233 shares of Dr. Martens stock. The stock was bought at an average price of GBX 64 per share, with a total value of £149.12.
• On Tuesday, April 14th, Giles Wilson bought 232 shares of Dr. Martens stock. The shares were bought at an average price of GBX 65 per share, for a total transaction of £150.80.

Dr. Martens Price Performance

Shares of DOCS traded up GBX 0.40 during mid-day trading on Tuesday, hitting GBX 72.50. 377,685 shares of the company traded hands, compared to its average volume of 8,721,683. Dr. Martens plc has a one year low of GBX 59.15 and a one year high of GBX 100.87. The company has a current ratio of 2.61, a quick ratio of 1.13 and a debt-to-equity ratio of 108.27. The business has a 50-day moving average of GBX 67.35 and a 200 day moving average of GBX 69.69. The stock has a market capitalization of £693.89 million, a price-to-earnings ratio of 30.21, a PEG ratio of 6.40 and a beta of 0.25.

Dr. Martens (LON:DOCS) last posted its quarterly earnings data on Tuesday, May 19th. The company reported GBX 4.20 earnings per share for the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. The firm had revenue of £764.90 million during the quarter. As a group, equities analysts expect that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DOCS has been the subject of a number of recent research reports. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 100 target price on shares of Dr. Martens in a research report on Tuesday, June 2nd. Berenberg Bank lowered their price objective on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of GBX 105.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.